Nicolas Brandone

Establishment of a pancreatic adenocarcinoma molecular gradient (PAMG) that predicts the clinical outcome of pancreatic cancer

J. Iovanna, N. Dusetti, L. Buscail, 2020, bioRxiv.

Validation of the QR1 Antibody for the Evaluation of PD-L1 Expression in Non–Small Cell Lung Adenocarcinomas

S. Lantuejoul, C. Mascaux, I. Rouquette, 2020, Applied immunohistochemistry & molecular morphology : AIMM.

Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC).

J. Mazières, C. Mascaux, F. Barlesi, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[Ovarian Sertoli-Leydig tumor: A tricky tumor].

A. Rome, A. Maués De Paula, C. Borrione, 2018, Annales de pathologie.

Pancreatic Cancer Organoids for Determining Sensitivity to Bromodomain and Extra-Terminal Inhibitors (BETi)

J. Iovanna, N. Dusetti, J. Cros, 2019, Front. Oncol..

A Molecular Gradient as a universal classifier of pancreatic adenocarcinoma that predicts tumor aggressiveness and mFOLFIRINOX sensitivity.

A. Reyniès, J. Iovanna, N. Dusetti, 2020 .

Immunoscore immune checkpoint using spatial quantitative analysis of CD8 and PD-L1 markers is predictive of the efficacy of anti- PD1/PD-L1 immunotherapy in non-small cell lung cancer

J. Galon, J. Adam, P. Tomasini, 2023, EBioMedicine.

[A solid variant of a serous cystadenocarcinoma of the pancreas].

B. Terris, F. Poizat, J. Thomassin-Piana, 2016, Annales de pathologie.

Abstract 5529: PD-L1 and CD8 IHC dual assessment in NSCLC using the Halioseek® assay: A multicentric study

J. Galon, J. Adam, Y. Boumber, 2018, Clinical Research (Excluding Clinical Trials).

Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC).

J. Mazières, C. Mascaux, F. Barlesi, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.